What are Radiopharmaceuticals?
Radiopharmaceuticals are a special class of drugs that contain
a radioactive isotope
a radioactive isotope
Radiopharmaceuticals are a special class of drugs that contains
a radioactive isotope
These radioactive isotopes emit energy, which can be detected using specialized scanners to
provide an image (diagnostic agent), or can be used for therapeutic applications and treatment of
disease (radiotherapeutic agent).
Millions of patients receive radiopharmaceuticals annually for a wide variety of medical procedures
ranging from the assessment of cardiac function, to neurological conditions, and the staging and
treatment of cancer.
These radioactive isotopes emit energy, which can be detected using specialized scanners to
provide an image (diagnostic agent), or can be used for therapeutic applications and treatment of
disease (radiotherapeutic agent).
Millions of patients receive radiopharmaceuticals annually for a wide variety of medical procedures
ranging from the assessment of cardiac function, to neurological conditions, and the staging and
treatment of cancer.
Diagnostics
Diagnostic agents are used for imaging
and determining site of disease,
treatment selection, and monitoring
response to treatment
and determining site of disease,
treatment selection, and monitoring
response to treatment
Diagnostic agents are used for imaging
and determining site of disease,
treatment selection, and monitoring
response
to treatment
When administered to a patient, the diagnostic probes
accumulate at the site of disease. These sites appear as
coloured or dark regions on a positron emission
tomography (PET) or single-photon emission computed
tomography (SPECT) scan. CPDC currently works with
partners to discover and develop next-generation
diagnostic radiopharmaceuticals, as well as bringing
diagnostics to Canada that were previously commercially
unavailable in the Canadian market.
accumulate at the site of disease. These sites appear as
coloured or dark regions on a positron emission
tomography (PET) or single-photon emission computed
tomography (SPECT) scan. CPDC currently works with
partners to discover and develop next-generation
diagnostic radiopharmaceuticals, as well as bringing
diagnostics to Canada that were previously commercially
unavailable in the Canadian market.
When administered to a patient, the diagnostic probes
accumulate at the site of disease. These sites appear as
coloured or dark regions on a positron emission
tomography (PET) or single-photon emission computed
tomography (SPECT) scan. CPDC currently works with
partners to discover and develop next-generation
diagnostic radiopharmaceuticals, as well as bringing
diagnostics to Canada that were previously commercially
unavailable in the Canadian market.
Therapeutics
Therapeutic radiopharmaceuticals are
administered to a patient to selectively
seek out and deliver high energy
cell-killing radiation to the site of disease.
administered to a patient to selectively
seek out and deliver high energy
cell-killing radiation to the site of disease.
Therapeutic radiopharmaceuticals are
administered to a patient to selectively
seek out and deliver high energy
cell-killing radiation to the site of disease.
New therapeutic radiopharmaceuticals are being
designed to precisely target and kill cancer cells, while
sparing normal healthy tissue, and clearing rapidly from
blood and tissues. CPDC works with our partners to
discover and develop therapeutic radiopharmaceuticals
for unmet medical cancer needs.
designed to precisely target and kill cancer cells, while
sparing normal healthy tissue, and clearing rapidly from
blood and tissues. CPDC works with our partners to
discover and develop therapeutic radiopharmaceuticals
for unmet medical cancer needs.
New therapeutic radiopharmaceuticals are being
designed to precisely target and kill cancer cells, while
sparing normal healthy tissue, and clearing rapidly from
blood and tissues. CPDC works with our partners to
discover and develop therapeutic radiopharmaceuticals
for unmet medical cancer needs.
Theranostics
Theranostic agents are complimentary
pairs targeting the same biomarkers or
disease where one
radiopharmaceutical can be used for
diagnosis and the other for therapy
with the only difference being the
radioisotope.
pairs targeting the same biomarkers or
disease where one
radiopharmaceutical can be used for
diagnosis and the other for therapy
with the only difference being the
radioisotope.
Theranostic agents are complimentary
pairs targeting the same biomarkers or
disease where one
radiopharmaceutical can be used for
diagnosis and the other for therapy
with the only difference being the
radioisotope.
Theranostics is a combination of diagnostic and
therapeutic modalities. The imaging or therapeutic
capability of a radioisotope depend on their method of
decay (α, β (+/-), γ). Radioisotopes
undergoing α or β (-)
decay can be used for
therapy while those undergoing
β(+) or γ decay
can be used for imaging (diagnosis).
Theranostic pairs
used in the clinic currently
include 125I/131I , 68Ga/177Lu,
and 99mTc/223Ra amongst
others. CPDC works with our
partners to discover
and develop theranostic agents to
further
personalized medicine.
Theranostics is a combination of diagnostic and
therapeutic modalities. The imaging or therapeutic
capability of a radioisotope depend on their method of
decay (α, β (+/-), γ). Radioisotopes
undergoing α or β (-)
decay can be used for
therapy while those undergoing
β(+) or γ decay
can be used for imaging (diagnosis).
Theranostic pairs
used in the clinic currently
include 125I/131I, 68Ga/177Lu,
and 99mTc/223Ra amongst
others. CPDC works with our
partners to discover
and develop theranostic agents to
further
personalized medicine.
For more information on
radiopharmaceuticals, click here:
radiopharmaceuticals, click here:
